Eco-directed sustainable prescribing: Feasibility for reducing water contamination by drugs

Science of the Total Environment

Volumn 493, Issue , 2014, Pages 392-404

  Daughton, Christian G ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Active pharmaceutical ingredients; Drugs; Pharmacokinetics; Prescribing; Sustainable healthcare; Water pollution

Indexed keywords

WATER POLLUTION;

ACTIVE PHARMACEUTICAL INGREDIENTS; DRUGS; PRESCRIBING; WATER CONTAMINATION;

PHARMACOKINETICS;

PRESCRIPTION DRUG; DRUG; WATER POLLUTANT;

DRUG; DRUG PRESCRIBING; ENVIRONMENTAL FATE; HEALTH CARE; POLLUTION CONTROL; SUSTAINABILITY; WATER POLLUTION;

ARTICLE; DRUG CHOICE; ECO DIRECTED SUSTAINABLE PRESCRIBING; ENVIRONMENTAL IMPACT; PRESCRIPTION; SEWAGE; WASTE DISPOSAL; WATER POLLUTION CONTROL; ANALYSIS; ENVIRONMENTAL PROTECTION; FEASIBILITY STUDY; PREVENTION AND CONTROL; PROCEDURES; WATER POLLUTANT; WATER POLLUTION;

CONSERVATION OF NATURAL RESOURCES; FEASIBILITY STUDIES; PHARMACEUTICAL PREPARATIONS; WATER POLLUTANTS, CHEMICAL; WATER POLLUTION, CHEMICAL;

EID: 84904319699     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2014.06.013     Document Type: Article

References (77)

1. Barnes K.K., Kolpin D.W., Furlong E.T., Zaugg S.D., Meyer M.T., Barber L.B. A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States - I) groundwater. Sci Total Environ 2008, 402:192-200. 10.1016/j.scitotenv.2008.04.028.
2. Baum R., Luh J., Bartram J. Sanitation: a global estimate of sewerage connections without treatment and the resulting impact on MDG progress. Environ Sci Technol 2013, 47:1994-2000. 10.1021/es304284f.
3. Benet L.Z. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013, 102:34-42. 10.1002/jps.23359.
4. Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J 2011, 13:519-547. 10.1208/s12248-011-9290-9.
5. Blair B.D., Crago J.P., Hedman C.J., Treguer R.J.F., Magruder C., Royer L.S., et al. Evaluation of a model for the removal of pharmaceuticals, personal care products, and hormones from wastewater. Sci Total Environ 2013, 444:515-521. 10.1016/j.scitotenv.2012.11.103.
6. Bond G.R., Woodward R.W., Ho M. The growing impact of pediatric pharmaceutical poisoning. J Pediatr 2012, 160:265-270.e1. 10.1016/j.jpeds.2011.07.042.
7. Budnitz D.S., Salis S. Preventing medication overdoses in young children: an opportunity for harm elimination. Pediatrics 2011, 127:e1597-e1599. 10.1542/peds.2011-0926.
8. Burghardt L.C., Ayers J.W., Brownstein J.S., Bronstein A.C., Ewald M.B., Bourgeois F.T. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics 2013, 132:1-10. 10.1542/peds.2012-2978.
9. Charkoftaki G., Dokoumetzidis A., Valsami G., Macheras P. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations. Basic Clin Pharmacol Toxicol 2010, 106:168-172. 10.1111/j.1742-7843.2009.00506.x.
10. Coday B.D., Yaffe B.G.M., Xu P., Cath T.Y. Rejection of trace organic compounds by forward osmosis membranes: a literature review. Environ Sci Technol 2014, 48:3612-3624. 10.1021/es4038676.
11. Cohen P.A. Hazards of hindsight - monitoring the safety of nutritional supplements. N Engl J Med 2014, 370:1277-1280. 10.1056/NEJMp1315559.
12. Curfman G.D., Morrissey S., Drazen J.M. High-value health care - a sustainable proposition. N Engl J Med 2013, 369:1163-1164. 10.1056/NEJMe1310884.
13. Custodio J.M., Wu C.Y., Benet L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008, 60:717-733. 10.1016/j.addr.2007.08.043.
14. Daneshvar A. Source, occurrence, and fate of pharmaceuticals in natural waters 2012, 74. Doctoral dissertation, Swedish University of Agricultural Sciences, Uppsala, Sweden, [Available on: http://pub.epsilon.slu.se/9100/ (accessed 8 April 2014)].
15. D'Ascenzo G., Di Corcia A., Gentili A., Mancini R., Mastropasqua R., Nazzari M., et al. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci Total Environ 2003, 302:199-209. 10.1016/S0048-9697(02)00342-X.
16. Daughton C.G. Pharmaceuticals and personal care products in the environment: overarching issues and overview. Pharmaceuticals and personal care products in the environment: scientific and regulatory issues 2001, 2-38. American Chemical Society, Washington, DC, [chapter 1]. C.G. Daughton, T.L. Jones-Lepp (Eds.).
17. Daughton C.G. Environmental stewardship and drugs as pollutants. Lancet 2002, 360:1035-1036. 10.1016/S0140-6736(02)11176-7.
18. Daughton C.G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 2003, 111:757-774. 10.1289/ehp.5947.
19. Daughton C.G. Pharmaceuticals as environmental pollutants: the ramifications for human exposure. International encyclopedia of public health 2008, 5:66-102. Academic Press, Oxford, England. K. Heggenhougen, S. Quah (Eds.).
20. Daughton C.G. Pharmaceutical ingredients in drinking water: overview of occurrence and significance of human exposure 2010, American Chemical Society, Washington, DC, [chapter 2]. R.U. Halden (Ed.).
21. Daughton C.G. Drugs and the environment: stewardship & sustainability. NERL-LV-ESD 10/081, EPA/600/R-10/106 2010, 196. National Exposure Research Laboratory, Environmental Sciences Division, US EPA, Las Vegas, NV, [Available on: http://www.epa.gov/nerlesd1/bios/daughton/APM200-2010.pdf (accessed 8 April 2014)].
22. Daughton C.G. Pharmaceuticals in the environment: sources and their management. Analysis, removal, effects and risk of pharmaceuticals in the water cycle - occurrence and transformation in the environment 2013, 62:37-69. Elsevier, [chapter 2]. M. Petrovic, S. Perez, D. Barcelo (Eds.).
23. Daughton C.G. The Matthew Effect and widely prescribed pharmaceuticals lacking environmental monitoring: case study of an exposure-assessment vulnerability. Sci Total Environ 2014, 466-467:315-325.
24. Daughton C.G., Ruhoy I.S. Environmental footprint of pharmaceuticals: the significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 2009, 28:2495-2521. 10.1897/08-382.1.
25. Daughton C.G., Ruhoy I.S. Green pharmacy and PharmEcovigilance: prescribing and the planet. Expert Rev Clin Pharmacol 2011, 4:211-232. 10.1586/ecp.11.6.
26. Daughton C.G., Ruhoy I.S. Lower-dose prescribing: minimizing "side effects" of pharmaceuticals on society and the environment. Sci Total Environ 2013, 443:324-337. 10.1016/j.scitotenv.2012.10.092.
27. Daughton C.G., Scuderi M.S.T. Pharmaceuticals and personal care products (PPCPs): relevant literature 2014, U.S. Environmental Protection Agency, Las Vegas, NV, [a comprehensive bibliographic database of literature references; first implemented 19 February 2008].
28. Deblonde T., Hartemann P. Environmental impact of medical prescriptions: assessing the risks and hazards of persistence, bioaccumulation and toxicity of pharmaceuticals. Public Health 2013, 127:312-317. 10.1016/j.puhe.2013.01.026.
29. Debroux J.-F., Soller J.A., Plumlee M.H., Kennedy L.J. Human health risk assessment of non-regulated xenobiotics in recycled water: a review. Hum Ecol Risk Assess 2012, 18:517-546. 10.1080/10807039.2012.672883.
30. Deo R.P. Pharmaceuticals in the surface water of the USA: a review. Curr Environ Health Rep 2014, 1:113-122. 10.1007/s40572-014-0015-y.
31. Deo R.P., Halden R.U. Pharmaceuticals in the built and natural water environment of the United States. Water 2013, 5:1346-1365. 10.3390/w5031346.
32. Desbrow C., Routledge E.J., Brighty G.C., Sumpter J.P., Waldock M. Identification of estrogenic chemicals in STW effluent. 1. Chemical fractionation and in vitro biological screening. Environ Sci Technol 1998, 32:1549-1558.
33. Focazio M.J., Kolpin D.W., Barnes K.K., Furlong E.T., Meyer M.T., Zaugg S.D., et al. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States - II) untreated drinking water sources. Sci Total Environ 2008, 402:201-216. 10.1016/j.scitotenv.2008.02.021.
34. Gao L., Shi Y., Li W., Niu H., Liu J., Cai Y. Occurrence of antibiotics in eight sewage treatment plants in Beijing, China. Chemosphere 2012, 86:665-671. 10.1016/j.chemosphere.2011.11.019.
35. Garci´a-Gala´n M.J., Gonza´lez Blanco S., Lo´pez Rolda´n R., Di´az-Cruz S., Barcelo´ D. Ecotoxicity evaluation and removal of sulfonamides and their acetylated metabolites during conventional wastewater treatment. Sci Total Environ 2012, 437:403-412. 10.1016/j.scitotenv.2012.08.038.
36. Glassmeyer S.T., Hinchey E.K., Boehme S.E., Daughton C.G., Ruhoy I.S., Conerly O., et al. Disposal practices for unwanted residential medications in the United States. Environ Int 2009, 35:566-572. 10.1016/j.envint.2008.10.007.
37. Hardikar S.R., Bhosale A.V., Chonkar A.D., Saindane R.A. Dissolution and bioavailability enhancement of carbamazepine. Int J Pharm Pharm Sci 2013, 5:395-400.
38. Hermening A., Grafe A.-K., Baktir G., Mutschler E., Spahn-Langguth H. Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. J Chromatogr B 2000, 741:129-144. 10.1016/S0378-4347(00)00041-4.
39. Hughes S.R., Kay P., Brown L.E. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environ Sci Technol 2013, 47:661-677. 10.1021/es3030148.
40. Jamei M., Turner D., Yang J., Neuhoff S., Polak S., Rostami-Hodjegan A., et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009, 11:225-237. 10.1208/s12248-009-9099-y.
41. Jones O.A.H., Voulvoulis N., Lester J.N. Human pharmaceuticals in wastewater treatment processes. Crit Rev Environ Sci Technol 2005, 35:401-427. 10.1080/10643380590956966.
42. Karanje R., Bhavsar Y., Jahagirdar K., Bhise K. Formulation and development of extended-release micro particulate drug delivery system of solubilized rifaximin. AAPS PharmSciTech 2013, 14:639-648. 10.1208/s12249-013-9949-x.
43. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 36:1202-1211. 10.1021/es011055j.
44. Kumar V., Johnson A.C., Nakada N., Yamashita N., Tanaka H. De-conjugation behavior of conjugated estrogens in the raw sewage, activated sludge and river water. J Hazard Mater 2012, 227-228:49-54. 10.1016/j.jhazmat.2012.04.078.
45. Lienert J., Burki T., Escher B.I. Reducing micropollutants with source control: substance flow analysis of 212 pharmaceuticals in faeces and urine. Water Sci Technol 2007, 56:87-96.
46. Liu Z.-h., Kanjo Y. An innovative analytical method for estrogen sulfates without deconjugation procedure. KSCE J Civ Eng 2012, 16:919-924. 10.1007/s12205-012-1666-6.
47. Luo Y., Guo W., Ngo H.H., Nghiem L.D., Hai F.I., Zhang J., et al. A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment. Sci Total Environ 2014, 473-474:619-641. 10.1016/j.scitotenv.2013.12.065.
48. Macheras P., Karalis V., Valsami G. Keeping a critical eye on the science and the regulation of oral drug absorption: a review. J Pharm Sci 2013, 102:3018-3036. 10.1002/jps.23534.
49. Mackay D., Hughes D.M., Romano M.L., Bonnell M. The role of persistence in chemical evaluations. Integr Environ Assess Manag 2014, [in press]. 10.1002/ieam.1545.
50. McConnell E.L., Fadda H.M., Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008, 364:213-226. 10.1016/j.ijpharm.2008.05.012.
51. NABP 2008-2009 report of the task force on medication collection programs 2009, 7. National Association of Boards of Pharmacy, Mount Prospect, IL, [Available on: https://www.nabp.net/news/2008-2009-report-of-the-task-force-on-medication-collection-programs; http://www.nabp.net/news/assets/08TF_Med_Collection_Programs.pdf (accessed 8 April 2014].
52. ONDCP National drug control strategy 2013, 95. Office of the National Drug Control Policy, Rockville, MD, (Available on: http://www.whitehouse.gov/ondcp/national-drug-control-strategy; http://www.whitehouse.gov//sites/default/files/ondcp/policy-and-research/ndcs_2013.pdf (accessed 8 April 2014)).
53. Ort C., Lawrence M.G., Rieckermann J., Joss A. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? A critical review. Environ Sci Technol 2010, 44:6024-6035. 10.1021/es100779n.
54. Ort C., Eppler J.M., Scheidegger A., Rieckermann J., Kinzig M., So¨rgel F. Challenges of surveying wastewater drug loads of small populations and generalisable aspects on optimizing monitoring design. Addiction 2014, 109:472-481. 10.1111/add.12405.
55. Panter G.H., Thompson R.S., Beresford N., Sumpter J.P. Transformation of a non-oestrogenic steroid metabolite to an oestrogenically active substance by minimal bacterial activity. Chemosphere 1999, 38:3579-3596. 10.1016/S0045-6535(98)00572-4.
56. Pham-The H., Garrigues T., Bermejo M., Gonza´lez-A´lvarez I., Monteagudo M.C., Cabrera-Pe´rez M.A´. Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number. Mol Pharm 2013, 10:2445-2461. 10.1021/mp4000585.
57. Phattanawasin P., Sotanaphun U., Sukwattanasinit T., Akkarawaranthorn J., Kitchaiya S. Quantitative determination of sibutramine in adulterated herbal slimming formulations by TLC-image analysis method. Forensic Sci Int 2012, 219:96-100. 10.1016/j.forsciint.2011.12.004.
58. Rice J., Westerhoff P., Wutich A. Assessment of de facto wastewater reuse across the USA: trends between 1980 and 2008. Environ Sci Technol 2013, 47:11099-11105. 10.1021/es402792s.
59. Ruhoy I.S., Daughton C.G. Beyond the medicine cabinet: an analysis of where and why medications accumulate. Environ Int 2008, 34:1157-1169. 10.1016/j.envint.2008.05.002.
60. Schiff G.D., Galanter W.L., Duhig J., Lodolce A.E., Koronkowski M.J., Lambert B.L. Principles of conservative prescribing. Arch Intern Med 2011, 171:1433-1440. 10.1001/archinternmed.2011.256.
61. Schiller C., Fro¨hlich C.P., Giessmann T., Siegmund W., Mo¨nnikes H., Hosten N., et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005, 22:971-979. 10.1111/j.1365-2036.2005.02683.x.
62. Snyder S.A., Adham S., Redding A.M., Cannon F.S., DeCarolis J., Oppenheimer J., et al. Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals. Desalination 2007, 202:156-181. 10.1016/j.desal.2005.12.052.
63. Stockholm County Council Environmentally classified pharmaceuticals 2012, 48. Stockholm City Council, Stockholm, Sweden, (Available on: http://www.janusinfo.se/Global/Miljo_och_lakemedel/miljobroschyr_2011_uppslag_eng.pdf (accessed 8 April 2014)).
64. Sui Q., Huang J., Deng S., Chen W., Yu G. Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in different biological wastewater treatment processes. Environ Sci Technol 2011, 45:3341-3348. 10.1021/es200248d.
65. Ternes T.A., Kreckel P., Mueller J. Behaviour and occurrence of estrogens in municipal sewage treatment plants - II. Aerobic batch experiments with activated sludge. Sci Total Environ 1999, 225:91-99. 10.1016/S0048-9697(98)00335-0.
66. USFDA Disposal of unused medicines: what you should know. list of medicines recommended for disposal by flushing 2009, [revised November 2013], US Food and Drug Administration, Rockville, MD, Available on: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm (accessed 8 April 2014).
67. USFDA FDA's medication health fraud page: list of tainted dietary supplements 2014, US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, [Available on: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?filter=&sortColumn=1d&sd=tainted_supplements_cder&page=1; http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/MedicationHealthFraud/default.htm (accessed 8 April 2014)].
68. van der Aa N.G.F.M., Dijkman E., Bijlsma L., Emke E., van de Ven B.M., Van Nuijs A.L.N., et al. Drugs of abuse and tranquilizers in Dutch surface waters, drinking water and wastewater: results of screening monitoring 2009 2011, 90. National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, [703719064/2010, Available on: http://dare.uva.nl/record/391403 (accessed 8 April 2014)].
69. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment - a review. Sci Total Environ 2012, 429:123-155. 10.1016/j.scitotenv.2012.04.028.
70. Wennmalm A˚´., Gunnarsson B. Experiences with the Swedish environment classification scheme. Green and sustainable pharmacy 2010, 243-249. Springer-Verlag, Berlin Heidelberg, Germany, [chapter 16]. K. Ku¨mmerer, M. Hempel (Eds.).
71. White R.E., Evans D.C., Hop C.E.C.A., Moore D.J., Prakash C., Surapaneni S., et al. Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary. Xenobiotica 2013, 43:219-225. 10.3109/00498254.2012.706724.
72. Williams R.T., Cook J.C. Exposure to pharmaceuticals present in the environment. Drug Inf J 2007, 41:133-141.
73. Writer J.H., Antweiler R.C., Ferrer I., Ryan J.N., Thurman E.M. In-stream attenuation of neuro-active pharmaceuticals and their metabolites. Environ Sci Technol 2013, 47:9781-9790. 10.1021/es402158t.
74. Wu C.-Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005, 22:11-23. 10.1007/s11095-004-9004-4.
75. Yan Q., Gao X., Chen Y.-P., Peng X.-Y., Zhang Y.-X., Gan X.-M., et al. Occurrence, fate and ecotoxicological assessment of pharmaceutically active compounds in wastewater and sludge from wastewater treatment plants in Chongqing, the Three Gorges Reservoir Area. Sci Total Environ 2014, 470-471:618-630. 10.1016/j.scitotenv.2013.09.032.
76. Zhang H., Liu P., Feng Y., Yang F. Fate of antibiotics during wastewater treatment and antibiotic distribution in the effluent-receiving waters of the Yellow Sea, northern China. Mar Pollut Bull 2013, 73:282-290. 10.1016/j.marpolbul.2013.05.007.
77. Zhou J.L., Zhang Z.L., Banks E., Grover D., Jiang J.Q. Pharmaceutical residues in wastewater treatment works effluents and their impact on receiving river water. J Hazard Mater 2009, 166:655-661. 10.1016/j.jhazmat.2008.11.070.